ME
Medifast, Inc.
MED · NYSE
$12.60 +0.48% (+$0.06)
1M +4.21%
Market Cap $139.9M
P/E Ratio -
Div. Yield -
ROE 12.68%
Bulios Fair Price
$16.17
28.3% upside
Current Price
$12.6
Undervalued Fair Value Overvalued
According to Bulios Fair Price, MED is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
63 /100
Fair P/B 0.71x
P/FCF 34.86x
P/S 0.44x
Growth
10 /100
Declining FCF growth 80.85%
Book val. growth 8.66%
Rev. growth 37.74%
Profitability
24 /100
Weak Net margin 8.08%
Op. margin 5.46%
FCF margin 1.27%
Quality
15 /100
Poor ROE 12.68%
ROA 9.83%
Asset turnover 1.22x
Debt
100 /100
Low Current ratio 4.86x
Debt/Equity 0.14x
Net debt/EBITDA N/A
Stability
57 /100
Moderate Rev. volatility 5.61%
EPS volatility 538.93%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about MED
Online
Sector
Consumer Cyclical
Industry
Personal Products & Services
CEO
Nicholas Johnson
Employees
380
Headquarters
Baltimore
Upcoming events
09 NOV
Earnings
Upcoming earnings report